Merck Stock Holds Steady Near 52-Week High Amid Strong Earnings Guidance

Merck stock has been trading close to its recent 52-week high as investors digest strong second-quarter revenue and full-year earnings guidance. The company reported $16.61 billion in revenue for the quarter, a 10% year-over-year increase, with its oncology franchise driving growth led by Keytruda.

The stock has gained 97.4% from its past year low of $77.58 and is trading at $153.21, just below its 52-week high of $154.49. Merck's full-year earnings per share guidance ranges from $2.66 to $2.76, aligning with analyst consensus.

The company's Keytruda, a PD-1 inhibitor, is central to its investment case and has become a standard of care in several cancers. Merck is also working on personalized mRNA cancer vaccines, including the intismeran autogene, which is being used alongside Keytruda in high-risk melanoma patients.